Background
Patients with HIV/hepatitis C co-infection have glucose and lipids metabolism alterations. Both HAART and HCV contribute to lipids and glucose metabolic damage. HAART-related insulin resistance contributes to the liver steato/fibrosis evolution. Fewer data on metabolic and hepatic tolerability are available in HIV/HCV co-infected patients who switch from ZDV/LMV to TDF/FTC or ABC/ LMV.
Methods
A total of 150 HIV/HCV co-infected subjects with HIV-RNA <50 copies/ml, on BID ZDV/LMV + atazanavir/ritonavir (ATV/rtv) >6 months were randomized 1:1:1 to continue this regimen or to switch to QD TDF/FTC+ATV/rtv or QD ABC/LMV +ATV/rtv. The primary end-point was change in insulin resistance, calculated with HOMA score (Homeostasis Model Assessment: fasting insulin UI/ml x glucose mmol/l/22.5) at 48 weeks. Secondary end-points included changes in absolute haemoglobin, AST, ALT, fasting lipids, CD4, and viral load. Liver fibrosis assessment by Fibroscan was planned at baseline and 96 weeks. Two sample t-test for between group comparison was used.
Summary of results
All 150 subjects were randomized: 49 to continue ZDV/ LMV; 50 to switch to TDF/FTC; and 51 to switch to ABC/ LMV. All patients were available for the 48-week analysis. Subjects were well matched for baseline characteristics and received a mean of 9 years prior ZDV/LMV. Median stiffness score was 7.9. Cirrhosis was in 13.5%. At 48 weeks, all randomized subjects maintained the same study therapy with VL <50 copies/ml. The change in median HOMA score was 0. 
Conclusion
Switching from ZDV/LMV to TDF/FTC or ABC/LMV in HIV/HCV persons treated with ATV/rtv provides a simplified QD regimen which maintains virological control and improves both lipid and glucose parameters without increase in hepatic toxicities.
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